Mary Beth Wire

Crippling life support for SARS-CoV-2 and other viruses through synthetic lethality

Direct and Catalytic C ‐Glycosylation of Arenes: Expeditious Synthesis of the Remdesivir Nucleoside**

Efficacy and Safety of Maribavir Dosed at 100 mg Orally Twice Daily for the Prevention of Cytomegalovirus Disease in Liver Transplant Recipients: A Randomized, Double-Blind, Multicenter Controlled Trial

Cytomegalovirus UL97 mutations in the era of ganciclovir and maribavir

Antiviral drugs for cytomegalovirus diseases

Steady‐state pharmacokinetics of once‐daily fosamprenavir/ritonavir and atazanavir/ritonavir alone and in combination with 20 mg omeprazole in healthy volunteers^*

Artesunate as a Potent Antiviral Agent in a Patient with Late Drug‐Resistant Cytomegalovirus Infection after Hematopoietic Stem Cell Transplantation

Effects of Acid‐Reducing Agents on the Pharmacokinetics of Lopinavir/Ritonavir and Ritonavir‐Boosted Atazanavir

Effects on maribavir susceptibility of cytomegalovirus UL97 kinase ATP binding region mutations detected after drug exposure in vitro and in vivo

Oral maribavir for treatment of refractory or resistant cytomegalovirus infections in transplant recipients

A comprehensive map of molecular drug targets

Guidelines for Preventing Infectious Complications among Hematopoietic Cell Transplantation Recipients: A Global Perspective

Conserved herpesvirus protein kinases

Virologic Characterization of Multidrug‐Resistant Cytomegalovirus Infection in 2 Transplant Recipients Treated with Maribavir

Ocular Drug Delivery

Chemical biology of natural indolocarbazole products: 30 years since the discovery of staurosporine

Fast selection of maribavir resistant cytomegalovirus in a bone marrow transplant recipient

Prodrugs—from Serendipity to Rational Design

Clinical Pharmacokinetic and Pharmacodynamic Profile of the HIV Integrase Inhibitor Elvitegravir

Resistance to Antibiotics: Are We in the Post-Antibiotic Era?

The early-onset torsion dystonia gene (DYT1) encodes an ATP-binding protein

The JAK/STAT signaling pathway: from bench to clinic

Maribavir prophylaxis for prevention of cytomegalovirus disease in recipients of allogeneic stem-cell transplants: a phase 3, double-blind, placebo-controlled, randomised trial

PROTAC targeted protein degraders: the past is prologue

The Third International Consensus Guidelines on the Management of Cytomegalovirus in Solid-organ Transplantation

Drug–Drug Interaction Studies: Regulatory Guidance and An Industry Perspective

l-Nucleoside enantiomers as antivirals drugs: A mini-review

Drug Interactions Between Peficitinib, an Orally Administered, Once-Daily Janus Kinase Inhibitor, and Rosuvastatin in Healthy Subjects

Antiretroviral Treatment of Adult HIV Infection

Alpharetroviral self-inactivating vectors produced by a superinfection-resistant stable packaging cell line allow genetic modification of primary human T lymphocytes

Prodrugs: design and clinical applications

C-Nucleosides: Synthetic Strategies and Biological Applications

Historical Perspective of Traditional Indigenous Medical Practices: The Current Renaissance and Conservation of Herbal Resources

Fluorine and Fluorinated Motifs in the Design and Application of Bioisosteres for Drug Design

Mapping the Efficiency and Physicochemical Trajectories of Successful Optimizations

The Medicinal Chemist’s Toolbox: An Analysis of Reactions Used in the Pursuit of Drug Candidates

Next Generation of Fluorine-Containing Pharmaceuticals, Compounds Currently in Phase II–III Clinical Trials of Major Pharmaceutical Companies: New Structural Trends and Therapeutic Areas

Study of Once-Daily Versus Twice-Daily Fosamprenavir plus Ritonavir Administered with Abacavir/Lamivudine Once Daily in Antiretroviral-Naïve HIV-1–Infected Adult Subjects

Update on Human Herpesvirus 6 Biology, Clinical Features, and Therapy

Antiviral Drug Resistance of Human Cytomegalovirus

Proteases and protease inhibitors in infectious diseases

Human Cytomegalovirus Resistance to Antiviral Drugs

Effect of Cell Culture Conditions on the Anticytomegalovirus Activity of Maribavir

Structural Alert/Reactive Metabolite Concept as Applied in Medicinal Chemistry to Mitigate the Risk of Idiosyncratic Drug Toxicity: A Perspective Based on the Critical Examination of Trends in the Top 200 Drugs Marketed in the United States

Concept and classification of dystonia.

Effects of food and antacids on the pharmacokinetics of eltrombopag in healthy adult subjects: Two single-dose, open-label, randomized-sequence, crossover studies

Fosamprenavir

A Randomized, Open-Label, 5-Period, Balanced Crossover Study to Evaluate the Relative Bioavailability of Eltrombopag Powder for Oral Suspension (PfOS) and Tablet Formulations and the Effect of a High-Calcium Meal on Eltrombopag Pharmacokinetics When Administered With or 2 Hours Before or After PfOS

Pharmacokinetics and Pharmacodynamics Clinical Pharmacokinetics, Platelet Response, and Safety of Eltrombopag at Supratherapeutic Doses of up to 200 mg Once Daily in Healthy Volunteers

Metabolism and Disposition of Eltrombopag, an Oral, Nonpeptide Thrombopoietin Receptor Agonist, in Healthy Human Subjects

Coadministration of Esomeprazole With Fosamprenavir Has No Impact on Steady-State Plasma Amprenavir Pharmacokinetics

Eltrombopag does not affect cardiac repolarization: results from a definitive QT_c study in healthy subjects

Eltrombopag increases plasma rosuvastatin exposure in healthy volunteers

Novel 4,4-Disubstituted Piperidine-Based C–C Chemokine Receptor-5 Inhibitors with High Potency against Human Immunodeficiency Virus-1 and an Improved human Ether-a-go-go Related Gene (hERG) Profile

Plasma Amprenavir Pharmacokinetics and Tolerability following Administration of 1,400 Milligrams of Fosamprenavir Once Daily in Combination with either 100 or 200 Milligrams of Ritonavir in Healthy Volunteers

Six-Week Randomized Controlled Trial To Compare the Tolerabilities, Pharmacokinetics, and Antiviral Activities of GW433908 and Amprenavir in Human Immunodeficiency Virus Type 1-Infected Patients

Fosamprenavir plus Ritonavir Increases Plasma Ketoconazole and Ritonavir Exposure, while Amprenavir Exposure Remains Unchanged

Phase I Safety and Pharmacokinetic Trials of 1263W94, a Novel Oral Anti-Human Cytomegalovirus Agent, in Healthy and Human Immunodeficiency Virus-Infected Subjects

Phase I Dose Escalation Trial Evaluating the Pharmacokinetics, Anti-Human Cytomegalovirus (HCMV) Activity, and Safety of 1263W94 in Human Immunodeficiency Virus-Infected Men with Asymptomatic HCMV Shedding

Effect of Antacids and Ranitidine on the Single-Dose Pharmacokinetics of Fosamprenavir